The National Agency for Food and Drug Administration and Control (NAFDAC) suspends the registration of Artemether/Lumefantrine dry powder for oral suspension due to concerns over its stability and effectiveness after reconstitution. NAFDAC states that all locally manufactured and imported multi-dose Artemether/Lumefantrine dry powder for oral suspension are affected by this decision. Stability studies reveal that … Continue reading NAFDAC Suspends Registration Of Artemether/Lumefantrine Oral Suspension Over Stability Concerns